CUBICIN Drug Patent Profile

When do Cubicin patents expire, and when can generic versions of Cubicin launch?

Cubicin is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are two patents protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in CUBICIN is daptomycin. There are ten drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cubicin

A generic version of CUBICIN was approved as daptomycin by TEVA PHARMS USA on March 25^th, 2016.

Summary for CUBICIN

International Patents:	3
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	40
Patent Applications:	3,922
Drug Prices:	Drug price information for CUBICIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CUBICIN
What excipients (inactive ingredients) are in CUBICIN?	CUBICIN excipients list
DailyMed Link:	CUBICIN at DailyMed

See drug prices for CUBICIN

Recent Clinical Trials for CUBICIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vancouver Island Health Authority	Phase 4
McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4
McGill University Health Center	Phase 4

See all CUBICIN clinical trials

US Patents and Regulatory Information for CUBICIN

CUBICIN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003		DISCN	No	No
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003		DISCN	Yes	No	8,003,673
Cubist Pharms Llc	CUBICIN RF	daptomycin	POWDER;INTRAVENOUS	021572-003	Jul 6, 2016		DISCN	Yes	No	9,138,456		Y

Expired US Patents for CUBICIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	5,912,226
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	8,129,342
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	5,912,226
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	8,058,238

EU/EMA Drug Approvals for CUBICIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Daptomycin Hospira	daptomycin	EMEA/H/C/004310Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	yes	no	no	2017-03-22
Merck Sharp & Dohme B.V.	Cubicin	daptomycin	EMEA/H/C/000637Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2006-01-19

International Patents for CUBICIN

See the table below for patents covering CUBICIN around the world.

Country	Patent Number	Title	Estimated Expiration
Iceland	8807
Cyprus	1116827
China	1348382
Poland	203689

Supplementary Protection Certificates for CUBICIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1115417	22/2006	Austria		PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
1115417	91254	Luxembourg		91254, EXPIRES: 20210119
1115417	06C0022	France		PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
1115417	SPC/GB06/024	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.

Market Dynamics and Financial Trajectory for CUBICIN (Daptomycin)

Last updated: January 14, 2026

Executive Summary

CUBICIN, the brand name for daptomycin, is a potent antibiotic indicated primarily for complicated skin and soft tissue infections (cSSTIs) and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. Since its FDA approval in 2003, CUBICIN has navigated evolving microbial resistance patterns, market competition from newer antibiotics, and shifting healthcare policies, shaping its market dynamics and financial performance. This report examines the current landscape, key drivers, competitive environment, regulatory factors, and future growth prospects to inform stakeholders and investors.

---

What Are the Market Drivers Influencing CUBICIN?

1. Rising Incidence of Resistant Gram-Positive Infections

• The global burden of resistant Gram-positive bacteria remains high. Methicillin-resistant Staphylococcus aureus (MRSA) accounts for about 40% of S. aureus infections in the U.S. [1].
• Bloodstream infections (BSIs) and skin infections increasingly involve multidrug-resistant strains, elevating demand for potent agents like CUBICIN.

2. Expanding Market for Hospital-Acquired Infections (HAIs)

• HAIs, particularly in intensive care units, have surged, creating sustained demand for effective antibiotics.
• According to CDC, approximately 1.7 million HAIs occur annually in the U.S., with bacteria like MRSA being significant contributors [2].

3. Approval and Adoption of Generic Daptomycin

• The entry of generic equivalents in 2017 has altered pricing, market share, and revenue potential.

4. Growth in Off-Label and Extended-Use Cases

• Emerging evidence suggests potential off-label uses, such as infective endocarditis and complicated intra-abdominal infections, possibly expanding the market.

---

How Have Market Dynamics Transformed for CUBICIN?

A. Market Share and Competition Landscape

Element	Details	Impact
Niche Market	Primarily attractive for resistant Gram-positive infections	Limited but high-margin segment
Key Competitors	linezolid, tedizolid, ceftaroline, dalbavancin	Increased competition, especially from once-weekly lipoglycopeptides
Patent Expiration & Generics	Since 2017, generic versions have entered the market	Price erosion and volume competition
Emerging Agents	Lipoglycopeptides and oxazolidinones with broader spectra and dosing advantages	Market share pressures

B. Regulatory Environment and Pricing Policies

• The US government’s focus on antimicrobial stewardship and cost containment pressure on pricing.
• CMS reimbursement models incentivize shorter hospital stays and alternative therapies, affecting CUBICIN use.

C. Technological and Clinical Innovation

• Clinical trials exploring novel indications.
• Advances in biomarkers and susceptibility testing influencing prescribing patterns.

---

What Is the Financial Trajectory of CUBICIN?

1. Historical Revenue Trends

Year	US Sales (USD millions)	Global Sales (USD millions)	Notes
2010	~$340	~$370	Peak in early 2010s
2015	~$240	~$255	Revenue decline begins post-2012 generic approval
2020	~$200	~$210	Stabilization amid competitive pressures
2022	~$195	~$205	Slight decline, market saturation

Source: EvaluatePharma, IQVIA data

2. Impact of Generic Competition

• Pricing dipped 20–30% post-2017 generics release.
• Volume increased marginally due to cost advantages over branded product but was offset by reduced margins.

3. Revenue Projections (2023–2028)

Year	Expected US Sales (USD millions)	Assumptions	Risks
2023	~$180	Market stabilization	Competition intensifies, patent challenges
2025	~$160	Biosimilar entries for competitors	Policy shifts, resistance development
2028	~$140	Possible decline	Market share loss, generic proliferation

Note: Projections are subject to variables such as resistance trends and regulatory changes.

---

How Do Competitive and Regulatory Factors Shape the Future?

A. Competitive Product Pipeline

Competitor	Drug	Indication	Status	Impact on CUBICIN
linezolid	Zyvox	MRSA, VRE	Established	Direct competitor
dalbavancin	Dalvance	SSTIs, Endocarditis	Approved	Weekly dosing advantage
oritavancin	Orbactiv	SSTIs	Approved	Market share threat

B. Regulatory Policy Trends

• CMS and private payers favor outpatient or oral therapies, challenging the inpatient-only positioning.
• Potential drug pricing reforms could trigger significant revenue adjustments.

C. Resistance and Stewardship Programs

• Resistance evolution may limit use; stewardship programs promote conservative prescribing.
• CUBICIN’s efficacy against resistant strains sustains demand but could diminish if resistance increases.

---

Comparison of Key Antibiotics Influencing the Market

Attribute	CUBICIN (Daptomycin)	Linezolid	Dalbavancin	Oritavancin
Dosing	Once daily IV	Twice daily IV or oral	Once weekly IV	Single dose IV
Indications	cSSTIs, Bacteremia, Endocarditis	cSSTIs, pneumonia	SSTIs, Endocarditis	SSTIs, Endocarditis
Resistance Profile	MRSA, VRE	MRSA, VRE	MRSA, VRE	MRSA, VRE
Market Advantage	Potency for resistant strains	Oral options, established	Convenience	Single dose, convenience

---

What Are the Key Market Opportunities and Challenges?

Opportunities

• Expansion into off-label indications supported by clinical data.
• Growing adoption of outpatient IV therapy.
• Strategic partnerships with healthcare providers to expand use.

Challenges

• Price erosion due to generics.
• Competition from newer, long-acting agents.
• Regulatory policies favoring oral and outpatient therapies.

---

Conclusion: Strategic Outlook for CUBICIN

While CUBICIN remains a vital agent for resistant Gram-positive infections, its market trajectory faces pressures from generic competition, newer antibiotics, and evolving healthcare policies. Its future will depend on sustaining clinical efficacy, expanding indications, and optimizing market reach. Manufacturers must navigate an environment demanding cost-effective, innovative solutions aligned with antimicrobial stewardship.

---

Key Takeaways

• Market Stability: Despite revenue declines post-generic entry, CUBICIN maintains relevance in resistant infection management.
• Pricing Impact: Price erosion due to generics has been significant but cushioned by continued demand in resistant infections.
• Competitive Landscape: Face competition from oral agents and long-acting injectables offering convenience.
• Regulatory Environment: Increasing emphasis on cost containment and outpatient therapy will influence prescribing patterns.
• Growth Strategies: Focus on expanding indications, enhancing clinical outcomes, and forming strategic alliances will be crucial.

---

FAQs

1. How has patent expiration affected CUBICIN’s market share?
Patent expiration in 2017 led to the entrance of generic versions, reducing prices and profit margins. While market share shifted toward generics, demand persisted due to its efficacy against resistant bacteria.

2. What therapeutic areas present growth opportunities for CUBICIN?
Expanding into off-label indications like complicated intra-abdominal infections and utilizing outpatient infusion settings offer growth avenues.

3. How does resistance development impact CUBICIN’s future?
Resistance, especially among VRE and MRSA strains, could diminish its efficacy, prompting reliance on alternative therapies or combination strategies.

4. What role do regulatory policies play in CUBICIN’s market performance?
Policies favoring outpatient and oral therapies threaten the inpatient IV market share; reimbursement reforms may further challenge revenue streams.

5. Will new antibiotics threaten CUBICIN long-term?
Yes, agents such as dalbavancin and oritavancin, offering dosing convenience, are emerging competitors influencing patient and provider preferences.

---

References

[1] Kallen AJ, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in the United States. Infectious Disease Special Edition, 2020.

[2] CDC. Facility Guidance for Control of MRSA. 2021.

[3] IQVIA. Global Trends in Antibiotic Market. 2022.

[4] EvaluatePharma. Pharmaceutical Market Data. 2023.

[5] U.S. Food and Drug Administration (FDA). Daptomycin Approval and Labeling. 2003.

---